Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9546-7. doi: 10.1073/pnas.0904560106. Epub 2009 Jun 8.

Authors

Daniel Steinberg¹, Joseph L Witztum

Affiliation

¹ Department of Medicine, University of California at San Diego, La Jolla, CA 92093-0682, USA.

No abstract available

Publication types

Comment

MeSH terms

Animals
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use*
Cholesterol, LDL / blood*
Drug Design
Humans
Mice
Proprotein Convertase 9
Proprotein Convertases
Receptors, LDL / metabolism
Serine Endopeptidases / drug effects*
Serine Endopeptidases / metabolism
Serine Proteinase Inhibitors / pharmacology
Serine Proteinase Inhibitors / therapeutic use*

Substances

Anticholesteremic Agents
Cholesterol, LDL
Receptors, LDL
Serine Proteinase Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases